{
    "root": "118a30fb-0931-4f4b-8afb-e68ca9462167",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "MOTEGRITY",
    "value": "20250303",
    "ingredients": [
        {
            "name": "PRUCALOPRIDE SUCCINATE",
            "code": "4V2G75E1CK"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3000",
            "code": "SA1B764746"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "FD&C BLUE NO. 2",
            "code": "L06K8R7DQK"
        }
    ],
    "indications": "MOTEGRITYÂ® is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.",
    "contraindications": "MOTEGRITY can be taken with or without food. The recommended dosage by patient population is shown in Table 1.\n                  \n                     Table 1:  Recommended Dosage Regimen and Dosage Adjustments by Population\n                     \n                     \n                     \n                        \n                           Population with  CIC\n                           Recommended Oral Dose Regimen\n                        \n                     \n                     \n                        \n                           Adults\n                           2 mg once daily\n                        \n                        \n                           Patients with severe renal impairment (creatinine clearance (CrCL) less than 30 mL/min) [see Use in Specific Populations (8.5 and 8.6)].\n                           1 mg once daily",
    "warningsAndPrecautions": "MOTEGRITY tablets containing 1 mg prucalopride are white to off-white, round, biconvex film-coated tablets debossed with \"PRU 1\" on one side and no debossing on the other side. They are supplied as:\n                  \n                     NDC 54092-546-01: HDPE bottle of 30 tablets, with child-resistant closure.\n                  \n                  MOTEGRITY tablets containing 2 mg prucalopride are pink, round, biconvex film-coated tablets debossed with \"PRU 2\" on one side and no debossing on the other side. They are supplied as:\n                  \n                     NDC 54092-547-01: HDPE bottle of 30 tablets, with child-resistant closure.",
    "adverseReactions": "MOTEGRITY is contraindicated in patients with:\n                  \n                     A history of hypersensitivity to MOTEGRITY. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed [(see Adverse Reactions (6.2)].\n                     Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn's disease, ulcerative colitis, and toxic megacolon/megarectum."
}